Sumika Fine Chemicals was merged into Sumitomo Chemical on 1 July, to form Sumitomo Chemical Pharmaceutical intermediates and Bulk divisions offering intermediates and API`s. The divisions focus on Contract Manufacturing (CMO) supported by specialised technology, and assets from pilot to bulk manufacturing of a very high regulatory status.Introduction of new technologies for drug synthesis is a major objective with the recent development of a high yield & high regiospecific Selective Amidation procedure for manufacture of amides, peptides, & oligopeptides; a Nickel catalysed Cross Coupling reaction for carbon-carbon bond formation;and a range of novel Purines & Nucleosides
Belgium
